A lipid mixing assay to accurately quantify the fusion of outer membrane vesicles.

The intermixing of phospholipids from opposing bilayers, or membrane fusion, is a naturally occurring process that can be leveraged to produce hybrid vesicle systems. Optimizing the production of these hybrid vesicles requires accurate, sensitive, and quantitative methods of the lipid mixing that occurs during fusion. A fluorescence-based assay that uses octadecyl-rhodamine B chloride to measure lipid mixing, or R18 assay, was developed by Hoekstra to investigate viral entry almost four decades ago. However, the R18 assay has so far only been used to measure heterotypic fusion events. Consequently, the fusion efficiencies that are calculated from the R18 assay underestimate the total number of fusion events and the true efficiency of vesicle fusions. In this article, we outline the experimental format and data analysis that is necessary to perform the R18 fusion assay and to accurately and reliably measure the true total fusion efficiency of outer membrane vesicles isolated from the Nissle 1917 strain of E. coli.

Induced fusion and aggregation of bacterial outer membrane vesicles: Experimental and theoretical analysis.

Recombinantly engineered bacterial outer membrane vesicles (OMVs) are promising vaccine delivery vehicles. The diversity of exogenous antigens delivered by OMVs can be enhanced by induced fusion of OMV populations. To date there are no reports of induced fusion of bacterial OMVs. Here we measure the pH and salt-induced aggregation and fusion of OMVs and analyze the processes against the Derjaguin-Landau-Verwey-Overbeek (DLVO) colloidal stability model. Vesicle aggregation and fusion kinetics were investigated for OMVs isolated from native E. coli (Nissle 1917) and lipopolysaccharide (LPS) modified E. coli (ClearColi) strains to evaluate the effect of lipid type on vesicle aggregation and fusion. Electrolytes and low pHs induced OMV aggregation for both native and modified LPS constructs, approaching a calculated fusion efficiency of ~25% (i.e. ~1/4 of collision events lead to fusion). However, high fusion efficiency was achieved for Nissle OMVs solely with decreased pH as opposed to a combination of low pH and increased divalent counterion concentration for ClearColi OMVs. The lipid composition of the OMVs from Nissle negatively impacted fusion in the presence of electrolytes, causing higher deviations from DLVO-predicted critical coagulation concentrations with monovalent counterions. The outcome of the work is a defined set of conditions under which investigators can induce OMVs to fuse and make various combinations of vesicle compositions.

Designer outer membrane vesicles as immunomodulatory systems - Reprogramming bacteria for vaccine delivery.

Vaccines often require adjuvants to be effective. Traditional adjuvants, like alum, activate the immune response but in an uncontrolled way. Newer adjuvants help to direct the immune response in a more coordinated fashion. Here, we review the opportunity to use the outer membrane vesicles (OMVs) of bacteria as a way to modulate the immune response toward making more effective vaccines. This review outlines the different types of OMVs that have been investigated for vaccine delivery and how they are produced. Because OMVs are derived from bacteria, they have compositions that may not be compatible with parenteral delivery in humans; therefore, we also review the strategies brought to bear to detoxify OMVs while maintaining an adjuvant profile. OMV-based vaccines can be derived from the pathogens themselves, or can be used as surrogate constructs to mimic a pathogen through the heterologous expression of specific antigens in a desired host source strain, and approaches to doing so are reviewed. Additionally, the emerging area of engineered pathogen-specific carbohydrate sequences, or glycosylated OMVs is reviewed and contrasted with protein antigen delivery. Existing OMV-based vaccines as well as their routes of administration round out the text. Overall, this is an exciting time in the OMV field as it matures and leads to more effective and targeted ways to induce desired pathogen-specific immune responses.